Psychopharmacological treatment of young people with substance dependence: A survey of prescribing practices in England

Child and Adolescent Mental Health

Volumn 19, Issue 2, 2014, Pages 102-109

  Bateman, Johanna ^a   Gilvarry, Eilish ^b   Tziggili, Maria ^c   Crome, Ilana B ^d   Mirza, Kah ^e   Mcardle, Paul ^f  

^a Child and Adolescent Psychiatry   (United Kingdom)

^b Plummer Court Alcohol and Drug Service ^*  (United Kingdom)

^c CITY UNIVERSITY   (United Kingdom)

^d KEELE UNIVERSITY   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f Fleming Nuffield Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ANTIDEPRESSANT AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CHLORDIAZEPOXIDE; CODEINE; DISULFIRAM; FLUOXETINE; LOFEXIDINE; MELATONIN; METHADONE; METHYLPHENIDATE; NALTREXONE; PSYCHOTROPIC AGENT; RISPERIDONE; ZOPICLONE;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; AGE; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; BENZODIAZEPINE DEPENDENCE; COMORBIDITY; DRUG DETOXIFICATION; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; OPIATE ADDICTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SUBSTANCE ABUSE; TREATMENT DURATION; UNITED KINGDOM; WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84897498399     PISSN: 1475357X     EISSN: 14753588     Source Type: Journal    
DOI: 10.1111/camh.12013     Document Type: Article

References (53)

1. Anderson, K.G., Ramo, D.E., Schulte, M.T., Cummins, K., & Brown, S.A. (2007). Substance use treatment outcomes for youth: Integrating personal and environmental predictors. Drug and Alcohol Dependence, 88, 42-48.
2. Auriacombe, M., Franques, P., & Tignol, J. (2001). Deaths attributable to methadone vs buprenorphine in France. Journal of the American Medical Association, 285, 45.
3. Behrendt, S., Wittchen, H.U., Hofler, M., Lieb, R., & Beesdo, K. (2009). Transitions from first substance use to substance use disorders in adolescence: Is early onset associated with a rapid escalation? Drug and Alcohol Dependence, 99, 68-78.
4. Bell, J., & Mutch, C. (2006). Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: A file review. Drug and Alcohol Review, 2, 167-171.
5. Bell, J., Trinh, L., Butler, B., Randall, D., & Rubin, G. (2009). Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction, 104, 1193-1200.
6. Boys, A., Marsden, J., Griffiths, P., Fountain, J., Stillwell, G., & Strang, J. (1999). Substance use among young people: The relationship between perceived functions and intentions. Addiction, 94(7), 1043-1050.
7. Bukstein, O.G., Bernet, W., Arnold, V., Beitchman, J., Shaw, J., Benson, R.S., ... & Ptakowski, K.K. (2005). Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 609-621.
8. Clark, D.B., Martin, C.S., & Cornelius, J.R. (2008). Adolescent-onset substance use disorders predict young adult mortality. Journal of Adolescent Health, 42, 637-639.
9. Crome, I., Christian, J., & Green, C. (1998). Tip of the National Iceberg?: Profile of adolescent patients prescribed methadone in an innovative community drug service. Drugs: Education, Prevention, and Policy, 7, 87-108.
10. Dawes, M.A., & Johnson, B.A. (2004). Pharmacotherapeutic trials in adolescent alcohol use disorders: Opportunities and challenges. Alcohol and Alcoholism, 39, 166-177.
11. Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive (2007). Drug misuse & dependence: UK guidelines on clinical management. Available from: http://www.nta.nhs.uk/publications/documents/clinical_guidelines_2007.pdf. [accessed 24 April 2013].
12. Department of Health, Gilvarry, E., & Britton, J. (2009). Guidance for the pharmacological management of substance misuse among young people. National Treatment Agency & Youth Justice Board. Available from: http://www.nta.nhs.uk/uploads/guidance_for_the_pharmacological_management_of_substance_misuse_among_young_people_1009.pdf. [accessed 24 April 2013].
13. Dixon, A., Howie, P., & Starling, J. (2005). Trauma exposure, posttraumatic stress, and psychiatric comorbidity in female juvenile offenders. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 798-806.
14. Frisher, M., Heatlie, H., & Hickman, M. (2006). Prevalence of problematic and injecting drug use for Drug Action Team areas in England. Journal of Public Health (Oxford, England), 28, 3-9.
15. Frisher, M., Heatlie, H., & Hickman, M. (2007). Validating estimates of problematic drug use in England. BMC Public Health, 7, 286.
16. Fuller, E., Clemens, S., Jotangia, D., Lynch, S., Nicholson, S., & Pigott, S. (2008). Drug use, smoking and drinking among young people in England in 2007. Health and Social Care Information Centre Available from: http://www.hscic.gov.uk/pubs/sdd07fullreport.
17. Galahad, S. (2004). Substance Misuse and the Juvenile Secure Estate. Available from: http://www.yjb.gov.uk/publications/Resources/Downloads/SubstanceMisuseJSEsummary.pdf. [last accessed 8 June 2013].
18. Gossop, M., Marsden, J., & Stewart, D. (2001). NTORS after five years: The National Treatment Outcome Research Study. Available from: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/publicationsandstatistics/publications/publicationspolicyandguidance/dh_4084908. [last accessed 24 April 2013].
19. Grella, C.E., Hser, Y.I., Joshi, V., & Rounds-Bryant, J. (2001). Drug treatment outcomes for adolescents with comorbid mental and substance use disorders. The Journal of Nervous and Mental Disease, 189, 384-392.
20. Hay, G., Ganno, M., MacDougall, J., Millar, T., Williams, K., Eastwood, C., & McKeganey, N. (2008). National and regional estimates of the prevalence of opiate use and/or crack cocaine use 2006/7. Research report 9 UK: Home Office.
21. HomeOffice. (1998). Tackling drugs to build a better Britain: The government's ten-year strategy for tackling drug misuse. London: Home office.
22. Hopfer, C.J., Khuri, E., Crowley, T.J., & Hooks, S. (2002). Adolescent heroin use: A review of the descriptive and treatment literature. Journal of Substance Abuse Treatment, 23, 231-237.
23. Kaminer, Y., Burleson, J.A., & Burke, R.H. (2008). Efficacy of outpatient aftercare for adolescents with alcohol use disorders: A randomized controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 47, 1405-1412.
24. Kelly, J.F., Brown, S.A., Abrantes, A., Kahler, C.W., & Myers, M. (2008). Social recovery model: An 8-year investigation of adolescent 12-step group involvement following inpatient treatment. Alcoholism, Clinical and Experimental Research, 32, 1468-1478.
25. Knudsen, H.K. (2009). Adolescent-only substance abuse treatment: Availability and adoption of components of quality. Journal of Substance Abuse Treatment, 36, 195-204.
26. Langenbach, T., Sponlein, A., Overfeld, E., Gaby, W., Niklas, Q., Scherbaum, N., ... & Hebebrand, J. (2010). Axis I comorbidity in adolescent inpatients referred for treatment of substance use disorders. Child and Adolescent Psychiatry and Mental Health, 4, 25.
27. Lingford-Hughes, A., Welch, S., Peters, L., & Nutt, D.J. (2012). BAP updated guidelines: Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: Recommendations from BAP. Journal of Psychopharmacology, 1-54.
28. Marsch, L.A., Bickel, W.K., Badger, G.J., Stothart, M.E., Quesnel, K.J., Stanger, C., ... & Brooklyn, J. (2005). Comparison of pharmacological treatments for opioid-dependent adolescents: A randomized controlled trial. Archives of General Psychiatry, 62, 1157-1164.
29. Marshall, J., & Mirza, K.A.H. (2007). Psychopharmacological treatment of young people with substance use disorder. In P.M. Eilish Gilvarry (Ed.), Alcohol, drugs and young people (pp. 197-216). London: Mac Keith Press.
30. Mattick, R.P., Kimber, J., Breen, C., & Davoli, M. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, CD002207.
31. Mills, K.L., Teesson, M., Darke, S., Ross, J., & Lynskey, M. (2004). Young people with heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment, 27, 67-73.
32. Murphy, R., & Roe, S. (2007). Drug misuse declared: Findings from the 2006/07 British Crime Survey, England and Wales. London: Home Office Statistical Bulletin.
33. National Treatment Agency. (2008). The role of CAMHS and addiction psychiatry in adolescent substance misuse: National Treatment Agency. London: National Treatment Agency.
34. National Treatment Agency. (2009a). Getting to grips with substance misuse among young people. London: National Treatment Agency.
35. National Treatment Agency (2009b). Getting to grips with substance misuse among young people: The data for 2007/08. England: National Treatment Agency.
36. National Treatment Agency (2011a). Statistics from the National Drug Treatment Monitoring System (NDTMS) 1 April 2010-31 March 2011. England: National Treatment Agency.
37. National Treatment Agency (2011b). Statistics from the National Drug Treatment Monitoring System (NDTMS) Statistics relating to young people England, 1 April 2010-31 March 2011. England: National Treatment Agency.
38. (NICE), N. I. f. C. E. (2007). Methadone and buprenorphine for the management of opioid dependence. London: National Institute for Clinical Excellence.
39. Perkonigg, A., Pfister, H., Hofler, M., Frohlich, C., Zimmermann, P., Lieb, R., & Wittchen, H.U. (2006). Substance use and substance use disorders in a community sample of adolescents and young adults: Incidence, age effects and patterns of use. European Addiction Research, 12, 187-196.
40. RCGP, R. C. o. G. P. (2011). Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care [Electronic Version]. Available from: http://www.rcgp.org.uk/revalidation-and-cpd/~media/Files/SMAH/RCGPGuidance-for-the-use-of-substitute-prescribing-in-the-treatment-of-opioid-dependence-in-primary-care-2011.ashx [acc-essed 24 April 2013].
41. RCPsych. (1997). Use of licensed medicines for unlicensed applications in psychiatric practice. CR142. London: Royal College of Psychiatrists.
42. Riggs, P.D., Mikulich-Gilbertson, S.K., Davies, R.D., Lohman, M., Klein, C., & Stover, S.K. (2007). A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Archives of Pediatrics and Adolescent Medicine, 161, 1026-1034.
43. Rodriguez-Llera, M.C., Domingo-Salvany, A., Brugal, M.T., Silva, T.C., Sanchez-Niubo, A., & Torrens, M. (2006). Psychiatric comorbidity in young heroin users. Drug and Alcohol Dependence, 84, 48-55.
44. (SAMSA), S. A. M. H. S. A. (2006). National survey on drug use and health: National results. North Carolina: Office of Applied Statistics, Department of Health and Human Services.
45. Scottish Goverment. (2008). The road to recovery: A new approach to tackling Scotland's drug problem. Edinburgh: Scottish Government.
46. Strang, J., Manning, V., Mayet, S., Ridge, G., Best, D., & Sheridan, J. (2007). Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995-2005. Addiction, 102, 761-770.
47. Strang, J., Sheridan, J., Hunt, C., Kerr, B., Gerada, C., & Pringle, M. (2005). The prescribing of methadone and other opioids to addicts: National survey of GPs in England and Wales. British Journal of General Practice, 55, 444-451.
48. Teesson, M., Mills, K., Ross, J., Darke, S., Williamson, A., & Havard, A. (2008). The impact of treatment on 3 years' outcome for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Addiction, 103, 80-88.
49. Tjepkema, M. (2004). Alcohol and illicit drug dependence. Health Reports, 15(Suppl.), 9-19.
50. Welsh Government. (2008). Working together to reduce harm the substance misuse strategy for Wales 2008-2018. Cardiff: Welsh Assembly Government.
51. Wilens, T.E., Adamson, J., Monuteaux, M.C., Faraone, S.V., Schillinger, M., Westerberg, D., & Biederman, J. (2008). Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents. Archives of Pediatrics and Adolescent Medicine, 162, 916-921.
52. Woody, G.E., Poole, S.A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., ... & Fudala, P. (2008). Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: A randomized trial. Journal of the American Medical Association, 300, 2003-2011.
53. Young, S.E., Corley, R.P., Stallings, M.C., Rhee, S.H., Crowley, T.J., & Hewitt, J.K. (2002). Substance use, abuse and dependence in adolescence: Prevalence, symptom profiles and correlates. Drug and Alcohol Dependence, 68, 309-322.